Orphan Drug Designation For Remdesivir Is 'Consistent' With Precedent, Former FDA Lawyer Says

Attorney who drafted Orphan Drug Act implementing regs says companies need incentive to develop a treatment that may not be available until crisis passes; KEI is mulling citizen petition to request revocation of the designation for Gilead's investigational COVID-19 product.